Treatment of metabolic disorders in feline animals

A method of treatment or prevention of a metabolic disorder in a feline animal comprising administering to the feline animal one or more active agents, where the one or more active agents consist of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof, wherein:

• the one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof comprises 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene or a pharmaceutically acceptable form thereof represented by the following formula:
• the metabolic disorder is selected from the group consisting of ketoacidosis, pre-diabetes, diabetes mellitus type 1, diabetes mellitus type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, diabetic remission, clinical conditions associated with pre-diabetes, diabetes type 1 or diabetes type 2, and combinations thereof;
• the feline is suffering from pre-diabetes or diabetes;
• and
• the one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof is administered at a dose no greater than 5 mg/kg body mass per day.